The refined structure of nascent HDL reveals a key functional domain for particle maturation and dysfunction

Nature Structural and Molecular Biology

Volumn 14, Issue 9, 2007, Pages 861-868

  Wu, Zhiping ^a   Wagner, Matthew A ^b   Zheng, Lemin ^a,d   Parks, John S ^c   Shy III, Jacinto M ^b   Smith, Jonathan D ^a   Gogonea, Valentin ^a,b   Hazen, Stanley L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND STATE UNIVERSITY   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d PrognostiX Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN; MUTANT PROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE;

ANIMAL CELL; ARTICLE; ATHEROMA; ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; DEUTERIUM HYDROGEN EXCHANGE; ENZYME ACTIVATION; ESCHERICHIA COLI; HEART PROTECTION; LIVER; MASS SPECTROMETRY; MISSENSE MUTATION; MOLECULAR MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN MODIFICATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; PROTEIN TARGETING;

CATALYSIS; CRYSTALLOGRAPHY, X-RAY; HUMANS; LIPOPROTEINS, HDL; MASS SPECTROMETRY; MODELS, MOLECULAR; OXIDATION-REDUCTION; PEROXIDASE; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; PROTEIN CONFORMATION;

EID: 34548501273     PISSN: 15459993     EISSN: 15459985     Source Type: Journal    
DOI: 10.1038/nsmb1284     Document Type: Article

References (43)

1. Barter, P.J. & Rye, K.A. Relationship between the concentration and antiatherogenic activity of high-density lipoproteins. Curr. Opin. Lipidol. 17, 399-403 (2006).
2. Rader, D.J. Mechanisms of disease: HDL metabolism as a target for novel therapies. Nat. Clin. Pract. Cardiovasc. Med. 4, 102-109 (2007).
3. Assmann, G. & Gotto, A.M., Jr. HDL cholesterol and protective factors in atherosclerosis. Circulation 109, III8-III14 (2004).
4. Plump, A.S., Scott, C.J. & Breslow, J.L. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. USA 91, 9607-9611 (1994).
5. Nissen, S.E. et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. J. Am. Med. Assoc. 290, 2292-2300 (2003).
6. Linsel-Nitschke, P. & Tall, A.R. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat. Rev. Drug Discov. 4, 193-205 (2005).
7. Ansell, B.J. et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 108, 2751-2756 (2003).
8. Nicholls, S.J., Zheng, L. & Hazen, S.L. Formation of dysfunctional high-density lipoprotein by myeloperoxidase. Trends Cardiovasc. Med. 15, 212-219 (2005).
9. Kontush, A. & Chapman, M.J. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol. Rev. 58, 342-374 (2006).
10. Tall, A.R. CETP inhibitors to increase HDL cholesterol levels. N. Engl. J. Med. 356, 1364-1366 (2007).
11. Nissen, S.E. et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med. 356, 1304-1316 (2007).
12. Kastelein, J.J. et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Engl. J. Med. 356, 1620-1630 (2007).
13. Zheng, L. et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J. Clin. Invest. 114, 529-541 (2004).
14. Peng, D.Q. et al. Tyrosine modification is not required for myeloperoxidase-induced loss of apolipoprotein A-I functional activities. J. Biol. Chem. 280, 33775-33784 (2005).
15. Zheng, L. et al. Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages. J. Biol. Chem. 280, 38-47 (2005).
16. Bergt, C. et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc. Natl. Acad. Sci. USA 101, 13032-13037 (2004).
17. Shao, B. et al. Tyrosine 192 in apolipoprotein A-I is the major site of nitration and chlorination by myeloperoxidase, but only chlorination markedly impairs ABCA1-dependent cholesterol transport. J. Biol. Chem. 280, 5983-5993 (2005).
18. Ajees, A.A., Anantharamaiah, G.M., Mishra, V.K., Hussain, M.M. & Murthy, H.M. Crystal structure of human apolipoprotein A-I: insights into its protective effect against cardiovascular diseases. Proc. Natl. Acad. Sci. USA 103, 2126-2131 (2006).
19. Li, Y., Kijac, A.Z., Sligar, S.G. & Rienstra, C.M. Structural analysis of nanoscale self-assembled discoidal lipid bilayers by solid-state NMR spectroscopy. Biophys. J. 91, 3819-3828 (2006).
20. Segrest, J.P. et al. A detailed molecular belt model for apolipoprotein A-I in discoidal high density lipoprotein. J. Biol. Chem. 274, 31755-31758 (1999).
21. Maiorano, J.N., Jandacek, R.J., Horace, E.M. & Davidson, W.S. Identification and structural ramifications of a hinge domain in apolipoprotein A-I discoidal high-density lipoproteins of different size. Biochemistry 43, 11717-11726 (2004).
22. Silva, R.A., Hilliard, G.M., Li, L., Segrest, J.P. & Davidson, W.S. A mass spectrometric determination of the conformation of dimeric apolipoprotein A-I in discoidal high density lipoproteins. Biochemistry 44, 8600-8607 (2005).
23. Bhat, S., Sorci-Thomas, M.G., Alexander, E.T., Samuel, M.P. & Thomas, M.J. Intermolecular contact between globular N-terminal fold and C-terminal domain of ApoA-I stabilizes its lipid-bound conformation: studies employing chemical cross-linking and mass spectrometry. J. Biol. Chem. 280, 33015-33025 (2005).
24. Thomas, M.J., Bhat, S. & Sorci-Thomas, M.G. The use of chemical cross-linking and mass spectrometry to elucidate the tertiary conformation of lipid-bound apolipoprotein A-I. Curr. Opin. Lipidol. 17, 214-220 (2006).
25. Zannis, V.I., Chroni, A. & Krieger, M. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J. Mol. Med. 84, 276-294 (2006).
26. Alexander, E.T. et al. Apolipoprotein A-I helix 6 negatively charged residues attenuate lecithin-cholesterol acyltransferase (LCAT) reactivity. Biochemistry 44, 5409-5419 (2005).
27. Mishra, V.K. et al. Association of a model class A (apolipoprotein) amphipathic alpha helical peptide with lipid: high resolution NMR studies of peptide.lipid discoidal complexes. J. Biol. Chem. 281, 6511-6519 (2006).
28. Minnich, A. et al. Site-directed mutagenesis and structure-function analysis of the human apolipoprotein A-I. Relation between lecithin-cholesterol acyltransferase activation and lipid binding. J. Biol. Chem. 267, 16553-16560 (1992).
29. Sorci-Thomas, M.G., Curtiss, L., Parks, J.S., Thomas, M.J. & Kearns, M.W. Alteration in apolipoprotein A-I 22-mer repeat order results in a decrease in lecithin:cholesterol acyltransferase reactivity. J. Biol. Chem. 272, 7278-7284 (1997).
30. Banka, C.L., Bonnet, D.J., Black, A.S., Smith, R.S. & Curtiss, L.K. Localization of an apolipoprotein A-I epitope critical for activation of lecithin-cholesterol acyltransferase. J. Biol. Chem. 266, 23886-23892 (1991).
31. Borhani, D.W., Rogers, D.P., Engler, J.A. & Brouillette, C.G. Crystal structure of truncated human apolipoprotein A-I suggests a lipid-bound conformation. Proc. Natl. Acad. Sci. USA 94, 12291-12296 (1997).
32. Rogers, D.P. et al. Truncation of the amino terminus of human apolipoprotein A-I substantially alters only the lipid-free conformation. Biochemistry 36, 288-300 (1997).
33. Martin, D.D., Budamagunta, M.S., Ryan, R.O., Voss, J.C. & Oda, M.N. Apolipoprotein A-I assumes a "looped belt" conformation on reconstituted high density lipoprotein. J. Biol. Chem. 281, 20418-20426 (2006).
34. Furbee, J.W., Jr., Sawyer, J.K. & Parks, J.S. Lecithin:cholesterol acyltransferase deficiency increases atherosclerosis in the low density lipoprotein receptor and apolipoprotein E knockout mice. J. Biol. Chem. 277, 3511-3519 (2002).
35. Lambert, G. et al. Analysis of glomerulosclerosis and atherosclerosis in lecithin cholesterol acyltransferase-deficient mice. J. Biol. Chem. 276, 15090-15098 (2001).
36. Lee, R.G. et al. Plasma cholesteryl esters provided by lecithin:cholesterol acyltransferase and acyl-coenzyme a:cholesterol acyltransferase 2 have opposite atherosclerotic potential. Circ. Res. 95, 998-1004 (2004).
37. Hovingh, G.K. et al. Compromised LCAT function is associated with increased atherosclerosis. Circulation 112, 879-884 (2005).
38. Hovingh, G.K. et al. Inherited disorders of HDL metabolism and atherosclerosis. Curr. Opin. Lipidol. 16, 139-145 (2005).
39. Matz, C.E. & Jonas, A. Micellar complexes of human apolipoprotein A-I with phosphatidylcholines and cholesterol prepared from cholate-lipid dispersions. J. Biol. Chem. 257, 4535-4540 (1982).
40. Sali, A. & Blundell, T.L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234, 779-815 (1993).
41. Guex, N. & Peitsch, M.C. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18, 2714-2723 (1997).
42. Chisholm, J.W., Gebre, A.K. & Parks, J.S. Characterization of C-terminal histidine-tagged human recombinant lecithin:cholesterol acyltransferase. J. Lipid Res. 40, 1512-1519 (1999).
43. Parks, J.S., Gebre, A.K. & Furbee, J.W. Lecithin-cholesterol acyltransferase. Assay of cholesterol esterification and phospholipase A2 activities. Methods Mol. Biol. 109, 123-131 (1999).